CLYM

Climb Bio, Inc.

Healthcare
Biotechnology
$816M market cap

Forecast run · Sep 14, 2026Upside rank 184 of 3,136

Model Signal

ForecastQ Daily Probabilities

67.1%

52.3%

47.6%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$14.25

Price target$26.55

Implied move+86.3%

Analysts7

ForecastQ Portfolios

CLYM is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.